Portola Pharmaceuticals Inc. (PTLA)’s Financial Results Comparing With Sesen Bio Inc. (NASDAQ:SESN)

Since Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Sesen Bio Inc. (NASDAQ:SESN) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Portola Pharmaceuticals Inc. 34.63M 56.85 353.46M -5.38 0.00
Sesen Bio Inc. N/A 0.00 33.48M -0.67 0.00

Table 1 highlights Portola Pharmaceuticals Inc. and Sesen Bio Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Portola Pharmaceuticals Inc. -1,020.68% -136.3% -69.7%
Sesen Bio Inc. 0.00% -85.7% -33.6%

Volatility & Risk

Portola Pharmaceuticals Inc.’s current beta is 2.04 and it happens to be 104.00% more volatile than Standard and Poor’s 500. Competitively, Sesen Bio Inc. is 198.00% more volatile than Standard and Poor’s 500, because of the 2.98 beta.

Liquidity

The current Quick Ratio of Portola Pharmaceuticals Inc. is 6.5 while its Current Ratio is 6.6. Meanwhile, Sesen Bio Inc. has a Current Ratio of 9.1 while its Quick Ratio is 9.1. Sesen Bio Inc. is better positioned to pay off its short-term and long-term debts than Portola Pharmaceuticals Inc.

Analyst Ratings

In next table is delivered Portola Pharmaceuticals Inc. and Sesen Bio Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Portola Pharmaceuticals Inc. 0 2 0 2.00
Sesen Bio Inc. 0 0 0 0.00

$31 is Portola Pharmaceuticals Inc.’s consensus target price while its potential upside is 4.59%.

Institutional and Insider Ownership

Portola Pharmaceuticals Inc. and Sesen Bio Inc. has shares held by institutional investors as follows: 0% and 49.9%. Insiders held 1.3% of Portola Pharmaceuticals Inc. shares. Competitively, 6.35% are Sesen Bio Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Portola Pharmaceuticals Inc. -4.39% 9.6% -24.91% -51.31% -60.37% -57.09%
Sesen Bio Inc. -8.67% 2.6% -30.4% -37.05% 132.76% 94.82%

For the past year Portola Pharmaceuticals Inc. had bearish trend while Sesen Bio Inc. had bullish trend.

Summary

Sesen Bio Inc. beats Portola Pharmaceuticals Inc. on 7 of the 10 factors.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.